

Table S1: Clinical features of study participants, stratified by group A-E

	A	B	C	D	E
n	18	40	46	37	60
Gender (% male)	22.2%	22.5%	54.3%	64.9%	75.0%
Age (years, mean (SD))	32.9 (12.7)	36.0 (11.8)	58.0 (16.9)	64.4 (15.1)	57.0 (14.9)
Days from COVID-19 symptoms to enrollment (days, mean (SD))	NA	6.5 (2.9)	11.4 (6.7)	10.6 (8.1)	24.6 (14.3)
COVID-19 chest radiology	NA	NA	50.0%	89.2%	100%
Non-COVID19 admissions	NA	NA	30.2%	8.1%	6.7%
Haemoglobin (g/L, mean (SD))	NA	NA	124.8 (16.0)	121.6 (18.0)	95.2 (16.8)
Serum creatinine (μmol/L, mean (SD))	NA	NA	82.9 (40.1)	117.5 (154.7)	103.5 (129.3)
Serum albumin (g/L, mean (SD))	NA	NA	32.4 (7.1)	28.0 (6.3)	24.4 (7.2)
LOS (days, median (IQR))	NA	NA	4 (1.25-10)	10 (6-16)	44 (33.7-63.2)
Admitted to ITU	NA	NA	0%	13.5%	90.0%
Deceased in hospital	NA	NA	2.2%	0.0%	30.0%
Hypertension	NA	NA	47.8%	43.2%	48.3%
CAD	NA	NA	8.7%	24.3%	16.7%
Other heart condition	NA	NA	10.9%	18.9%	13.3%
Diabetes mellitus	NA	NA	26.1%	29.7%	43.3%
CKD	NA	NA	8.7%	16.2%	8.3%
PVD	NA	NA	6.5%	8.1%	8.3%
CVA/TIA	NA	NA	10.9%	2.7%	6.7%
COPD	NA	NA	6.5%	18.9%	5.0%
Asthma	NA	NA	21.7%	10.8%	10.0%
Other lung disease	NA	NA	10.9%	16.2%	10.0%
Cancer	NA	NA	4.4%	5.4%	1.7%
Haematological cancer	NA	NA	2.2%	5.4%	0.0%
Corticosteroids	NA	NA	19.6%	10.8%	10.0%
Immunosuppressive treatment	NA	NA	17.4%	16.2%	5.0%

SD is standard deviation, and IQR is interquartile range.

COVID-19 chest radiology: chest X-ray/ CT scan showed changes compatible with COVID-19, as opposed to normal findings or lung changes diagnostic of other conditions.

Non-COVID19 admissions: cases where COVID-19 was diagnosed during the hospital stay in patients initially admitted to hospital for reasons unrelated to COVID-19

Haemoglobin, serum albumin and serum creatinine: results from routine lab tests on the day of study enrollment, or closest result up to 2 days before. The included test results are available for at least for 75% of each severity group.

LOS: length of hospital stay (days from hospital admission to discharge, transfer or death in hospital)

Hypertension: history of hypertension, defined as blood pressure $\geq 140/80$ on multiple occasions, or on treatment with any medication explicitly employed to reduce blood pressure

CAD: history of coronary artery disease, defined as myocardial infarction, angina, coronary artery stenting or coronary artery bypass grafting

Other heart condition: history of any other chronic cardiac disease (not CAD/hypertension), e.g. heart failure, congenital heart disease, cardiomyopathy, rheumatic heart disease

CKD: history of chronic kidney disease, defined as any of estimated glomerular filtration rate $< 60 \text{ mL/min}/1.73\text{m}^2$, dialysis or kidney transplant

PVD: history of peripheral vascular disease, defined as intermittent claudication or past bypass for chronic arterial insufficiency, history of gangrene or acute arterial insufficiency, or thoracic/abdominal aneurysm ($\geq 6 \text{ cm}$)

CVA/TIA: history of a cerebrovascular accident or transient ischemic attacks

COPD: history of chronic obstructive pulmonary disease

Other lung disease: history of other chronic pulmonary disease (non asthma/COPD), e.g. cystic fibrosis, bronchiectasis, interstitial lung disease

Cancer: current solid organ malignancy (active or in the last 5 years), except non-melanoma skin cancers

Corticosteroids: history of treatment with systemic corticosteroids in the 14 days prior to hospital admission/presentation

Immunosuppressive treatment: history of treatment with immunosuppressants (excluding corticosteroids) in the 14 days prior to hospital admission/presentation, or chemotherapy/biologic drugs in the previous 6 months

Table S2: patients excluded because of extreme confounding comorbidities

Study ID	Patient profile
CV0266	Metastatic lung adenocarcinoma on immunotherapy and chemotherapy, presentation with new onset heart failure and pulmonary oedema, borderline positive COVID-19 PCR on nasopharyngeal swab, but no other clinical features of COVID-19
CV0258	Prolonged hospital admission for new diagnosis of acute myeloid leukemia with suspected leukemic lung infiltration and fungal chest infection, commenced on chemotherapy. COVID-19 PCR negative at hospital admission and subsequently positive.
CV0143	Mild COVID-19 symptoms, admitted for extensive necrotizing fasciitis/mediastinitis, treated with surgical debridement and complicated by massive haemorrhage. Enrolled in the study in the ITU after surgery.
CV0192	Emergency splenectomy following trauma. Fever and pneumonia in the post-op, with radiology in keeping with aspiration. Borderline positive COVID-19 PCR on nasopharyngeal swab.
CV0033	Lymphoma on palliative chemotherapy, initially admitted for interstitial pneumonia and neutropenia and treated as Pneumocystis pneumonia. COVID-19 PCR initially negative 4x and subsequently positive after 2 weeks.
CV0313	End-stage alcoholic cirrhosis with variceal bleeding and hepatic encephalopathy, admitted for transjugular intrahepatic portosystemic shunt procedure. Positive COVID-19 PCR on nasopharyngeal swab, initially with normal chest X-ray. Subsequently developed severe chest infection with bronchoalveolar lavage positive for Gram negative organisms and negative for COVID-19 PCR.

Table S3: WGCNA module gene list and heme GSEA intersect genes (shared between C/D/E in the leading edge)

Csv file

Table S4: Antibody staining panel used for flow cytometry (FACS) analysis. Aliquots of PBMCs were stained with one of two antibody combinations prior to FACS analysis. The laser and band pass filter combination used to detect each antibody is also shown.

Panel	Laser	BPF	Antigen	Fluorophore	Clone	Vendor	Cat
DCs and monocytes	355	379/28	CD40	BUV395	5C3	BD	565202
		515/30	CD16	BUV496	3G8	BD	612944
		560/40					
		670/30	CD3	BUV661	UCHT1	BD	612964
		740/35	CD86	BUV737	FUN-1	BD	612784
		820/60	CD45	BUV805	HI30	BD	612891
	405	450/50					
		515/20	Zombie Aqua			BioLegend	423101
		585/15	CD45RA	BV570	HI100	BioLegend	304132
		605/40	CD141	BV605	1A4	BD	740421
	488	670/30	CCR7	BV650	G043H7	BioLegend	353234
		710/40	CD14	BV711	MφP9	BD	563372
		741/40					
		780/60	CD123	BV786	7G3	BD	564196
		525/50	CD56	FITC	MEM188	Thermo	MHCD5601
conventional T cells	561	610/20					
		685/35					
		715/30	CD32	BB700	FLI8.26	BD	742216
		780/60					
		585/15	CD304	PE	U21-1283	BD	565951
		610/20	CD163	PE-CF594	GHI/61	BD	562670
		670/30	CD80	PECy5	L307.4	BD	559370
		710/40					
		780/60	CD303	PE-Vio770	REA693	Miltenyi	130-110-321
		640	670/30	CD1c	AF647	F10/21A3	BD
conventional T cells	355	730/45	CD11c	AF700	B-ly6	BD	561352
		780/60	HLA-DR	APC-H7	G46-6	BD	561358
		379/28	CD3	BUV395	SK7	BD	564001
		515/30	CD4	BUV496	SK3	BD	612936
		560/40					
	670/30	670/30	CD38	BUV661	HIT2	BD	612969
		740/35	CD95	BUV737	DX2	BD	612790

	820/60	CD45RA	BUV805	HI100	BD	742020	
405	450/50	PD-1	BV421	<u>EH12.2H7</u>	BioLegend	329920	
	515/20	CD8b	BV480	2ST8.5H7	BD	746266	
	585/15	Zombie Yellow			BioLegend	423103	
	605/40	HLADR	BV605	L243	BioLegend	307640	
	670/30	CD69	BV650	FN50	BioLegend	310934	
	710/40	CD27	BV711	O323	BioLegend	302834	
	741/40						
	780/60	CD28	BV785	CD28.2	BioLegend	302950	
488	525/50	KLRG1	FITC	REA261	Miltenyi	130-103-640	
	610/20				-		
	685/35						
	715/30						
	780/60						
561	585/15	CD161	PE	HP-3G10	BioLegend	339904	
	610/20	CRTh2	PE-dazzle	BM16	BioLegend	350126	
	670/30	CD127	PECy5	eBioRDR5	Thermo	15-1278-42	
	710/40						
	780/60	CCR6	PECy7	G034E3	BioLegend	353418	
640	670/30						
	730/45	CXCR5	APC-R700	RF8B2	BD	565191	
	780/60	CCR7	APC-fire	G043H7	BioLegend	353246	
<hr/>							
non-conventional T cells.	355	379/28	CD3	BUV395	SK7	BD	564001
		515/30	CD4	BUV496	SK3	BD	612936
		560/40					
		670/30					
		740/35	TCRgd	BUV737	11F2	BD	748533
		820/60	CD28	BUV805	L293	BD	748474
	405	450/50	PD-1	BV421	<u>EH12.2H7</u>	BioLegend	329920
		515/20	CD8b	BV480	2ST8.5H7	BD	746266
		585/15	Zombie Yellow				
		605/40	HLADR	BV605	L243	BioLegend	307640

	488	525/50 610/20 685/35 715/30 780/60	KLRG1 TCR-DV2	FITC PerCP Cy5.5	REA261 B6	Miltenyi BioLegend	130-103-640 331424
	561	585/15 610/20 670/30 710/40 780/60	CD161 CD127 TCR-DV1	PE PECy5 PECy7	HP-3G10 eBioRDR5 TS8.2	BioLegend Thermo Thermo	15-1278-42 25-5679-42
	640	670/30 730/45 780/60	CCR5 TCR Vγ9 Vb11	AF647 AF700 APCVio770	HEK/1/85a B3 REA559	BioLegend BioLegend Miltenyi	313712 331318 130-108-735
<hr/>							
B cells	355	379/28 515/30 560/40 670/30 740/35 820/60	IgM CD19 CD38 IgD CD20	BUV395 BUV496 BUV661 BUV737 BUV805	G20-127 SJ25C1 HIT2 IA6-2 2H7	BD BD BD BD BD	
	405	450/50 515/20 515/20 515/20 515/20 585/15	CD39 CD3 CD14 CD15 CD193 Zombie Yellow	BV421 BV510 BV510 BV510 BV510	A1 UCHT1 63D3 W6D3 5.00E+08	BioLegend BioLegend BioLegend BioLegend BioLegend	
		605/40 670/30 710/40 741/40 780/60	HLADR CD71 CD27 CD73	BV605 BV650 BV711	L243 CY1G4 O323 AD2	BioLegend BioLegend BioLegend BioLegend	
	488	525/50 610/20 685/35 715/30 780/60	CD56 CD24	FITC BB700	MEM188 ML5	Thermo BD	

	561	585/15	IgA	PE	Polyclonal goat IgG	Jackson	
		610/20	CD138	PE-dazzle	DL-101	BioLegend	
		670/30	CD80	PECy5	L307.4	BD	
		710/40					
		780/60	CD86	PECy7	BU63	BioLegend	
	640	670/30	GLUT1	AF647	202915	BD	
		730/45	CXCR5	APC-R700	RF8B2	BD	
		780/60	IgG	APC-H7	G18-145	BD	
<hr/>							
T regulatory cells.	355	379/28	CD3	BUV395	SK7	BD	564001
		515/30	CD4	BUV496	SK3	BD	612936
		560/40					
		670/30					
		740/35					
		820/60	CD45RA	BUV805	HI100	BD	742020
	405	450/50	PD-1	BV421	<u>EH12.2H7</u>	BioLegend	329920
		515/20	CD8b	BV480	2ST8.5H7	BD	746266
		585/15	Zombie Yellow				
		605/40	HLADR	BV605	L243	BioLegend	307640
		670/30	CCR7	BV650	G043H7	BioLegend	353234
		710/40					
		741/40					
		780/60	CD73	Brilliant Violet 785™	AD2	BioLegend	344028
	488	525/50					
		610/20					
		685/35					
		715/30	CD127	PerCP efluor710	eBioRDR5	Thermo	46-1278-42
		780/60					
	561	585/15	CD25	PE	BC96	Thermo	12-0259-42
		610/20	Helios	Pedazzle	22F6	BioLegend	137232
		670/30					
		710/40					
		780/60	CCR4	PEVio770	REA279	Miltenyi	130-103-814
	640	670/30	FoxP3	APC	236A/E7	Thermo	17-4777-42
		730/45	CXCR5	APC-R700	RF8B2	BD	565191
		780/60	CD39	APC-fire	A1	BioLegend	328230

Supplementary Figure Legends

Figure S1: Swimmer plots for study patients in groups C, D and E. Arrows indicate days since start of COVID-19 symptoms (or since positive SARS-CoV-2 PCR test, if asymptomatic). Black boxes indicate the duration of hospital stay whilst enrolled in the study. If patients were transferred from other hospitals (as indicated by the triangle symbol), information relative to the time before transfer to one of the study hospitals may be missing. Research blood collection timepoints are indicated by open circle, and time of death by red cross for deceased patients. Degree of respiratory support is indicated by colour gradient as per the key provided. **A)** Information illustrated for patients in groups C, **B)** patients in group D, and **C)** patients in group E. **D)** SARS-CoV-2 PCR CT values over time across patient severity groups. CT values ≤ 38 were reported as a positive result. A discretionary CT number of 45 was assigned to samples with no detectable SARS-CoV-2 RNA. Each colour correspond to a different subject. Repeat measures for a single participant are linked by dashed line. Y axis is inverted.

Figure S2: Comparison of absolute cell counts derived by flow and mass cytometry. Scatter plots showing the correlation between cell population quantified by both flow and mass cytometry (cells/uL). Pearson correlation R value and p-values of correlation test are reported for each comparison.

Figure S3: Cellular changes over time in COVID-19 patients - extended figure 2 including the full cell dataset. **A)** Heatmap showing the log₂ fold change in median absolute cell count between COVID-19 patients and healthy controls, within severity categories and across 12-day time bins. Missing data are shown in grey. Wilcoxon test FDR adjusted p-values: * <0.05 , ** <0.005 , *** <0.0005 . **B)** Boxplots showing absolute counts (cells/uL) for all the cell populations, split by severity categories and 12-day time bins post screening (group A) or symptom onset (group B-E). Points are coloured based on asymptomatic or symptomatic classification for categories A and B respectively, normal or abnormal chest radiology (group C), and type of respiratory support at time of sampling (groups D and E), as per the key colour provided. **C)** Mixed-effects model with quadratic time trend showing the longitudinal trajectories of all the cell populations over time, grouped by severity. Nominal and adjusted p-values for the time x severity group interaction term are reported.

In **B**) and **C**) Grey band indicates interquartile range of the corresponding population in healthy controls. NIV/HF, non-invasive ventilation/high-flow oxygen; ECMO, extracorporeal membrane oxygenation. Hb, haemoglobin.

Figure S4: Whole blood transcriptomic signatures over time – extended figure 3. **A)** Annotation of Latent Factors used to perform the cell subset deconvolution shown in Fig.3A. **B)** and **C)** data derived from WGCNA. **B)** Dendrogram and heatmap showing the correlation between gene expression eigenmodules. **C)** Heatmap illustrating the correlation among whole blood co-expression gene modules (coloured blocks, y axis) and age, gender, steroid treatment, CRP levels, and the comparison between healthy controls and COVID-19 cases split by severity in 24 days bins (x axis). Pearson correlation and FDR corrected p-values are shown for each comparison. **D)** Annotation of modules that correlate with disease and/or severity. **E)** Correlation between SARS-CoV-2 PCR CT values and Interferon Signature Genes (IGS) module eigenvalues.

Figure S5: Multivariate analysis of immune-cell populations in early disease - extended figure 4.

A) Mixed-effect model with quadratic time trend showing the longitudinal trajectories of inflammatory characteristics, and boxplot at time of sampling (<=10 days post symptom onset), for individual in clusters 1 and 2. **B)** Mixed-effect model with quadratic time trend showing the longitudinal trajectories for all cell populations over time, for COVID-19 cases in clusters 1 and 2. Grey band indicates the interquartile range of the corresponding population in HCs. Nominal and adjusted p-values for the time x cluster interaction term are reported. Variable selection by sPLS-DA. **C)** PLS-DA showing discrimination of patient clusters 1 and 2 derived in Fig. 4B. **D)** Associated classification error rate of the predictive model across 10 iterations of 5-fold cross validation for components 1-10. **E)** Feature selection on components 1 and 2, determining 13 cell subsets as key contributors to cluster discrimination with minimal error. Unsupervised clustering of 13 selected cell types (normalised to the median of healthy controls), with original sample clusters and patient characteristics indicated.

Figure S6: SARS-CoV-2 specific T cell response – extended figure 5E. Spot forming unit (SFU) numbers of CD3 T cells secreting IFN γ in response to membrane, nucleocapsid and spike SARS-CoV-2 antigen stimulation, in patient samples from groups B, and D and E combined, one or two weeks post symptom onset.

Figure S7: Correlation plots – extended figure 7C. Heatmap showing the correlation between gene expression eigenmodules derived from whole blood RNASeq, absolute cell counts and inflammatory characteristics in COVID-19 patients collected within **A)** the first 24 days, or **B)** between 25-48 days post screening or symptom onset. Pearson correlation p-values: *p<0.05, **p<0.01 and ***p<0.001.

Figure S8: Flow cytometry gating strategy. **A)** B cell, **B)** non-conventional T cell, **C)** DCs and monocyte, **D)** T regulatory cells, and **E)** conventional T cell panels.

Figure S1

Swimmer plots for study patients (groups C/D/E)

Legend

- no supplemental oxygen
- supplemental oxygen
- NIV/HF
- invasive ventilation
- ECMO
- research bloods
- * asymptomatic
- ▽ admitted to other hospital
- transferred to other hospital
- X deceased

Arrows indicate days since start of COVID-19 symptoms (or since positive SARS-CoV-2 PCR test, if asymptomatic).


The black boxes highlight the time when study volunteers were admitted to the hospital where they were enrolled in the study.

If patients were transferred from other hospitals (as indicated by the triangle symbol), information relative to the time before transfer to one of the study hospitals may be missing.


A

Group C, 1 of 2


CV0002




CV0006




CV0007




CV0010




CV0011




CV0014



CV0015




CV0019




CV0031




CV0043




CV0045




CV0046



CV0050




CV0051




CV0073



CV0074




CV0080




CV0086




CV0093




CV0100




CV0104




CV0122




CV0125




CV0128




CV0145




CV0149




CV0150




CV0156




CV0159




CV0160



CV0186




CV0193




Group C, 2 of 2


CV0194




CV0195




CV0224




CV0225




CV0228




CV0233




CV0239




CV0254



CV0267




CV0300




CV0301




CV0302



CV0326




CV0329




Group D, 1 of 2

B




Group D, 2 of 2


CV0294




CV0299




CV0310



CV0322



CV0328




C

Group E, 1 of 2

CV0001




CV0003




CV0027




CV0034




CV0047




CV0052




CV0056




CV0099




CV0116




CV0118




CV0124




CV0129




CV0130




CV0134




CV0144




CV0172



CV0174




CV0176




CV0178




CV0180




CV0181



CV0190




CV0191




CV0197




CV0198




CV0199




CV0200




CV0201



CV0202



CV0203



CV0205



CV0207



Group E, 2 of 2


CV0208



CV0209



CV0212




CV0213



CV0214




CV0215




CV0216




CV0217




CV0218



CV0245




CV0246




CV0247




CV0248




CV0249




CV0250



CV0251




CV0272



CV0273




CV0277




CV0278




CV0279




CV0284



CV0285




CV0296




CV0306




CV0312



CV0327



CV0337



D




Figure S2: Comparison between cells identified by flow and mass cytometry







Figure S3: Cellular changes over time in COVID-19 patients - extended figure 2 including the full cell database

A











CD4 EMT

Likelihood ratio test: interaction uncorrected $p = 0.00032$ (**)





CD4 EMRA T

Likelihood ratio test: interaction uncorrected $p = 0.00047$ (**)




CD4 Total HLA-DR+CD38+ T


Likelihood ratio test: interaction uncorrected $p = 0.001$ (**)



CD4 CM HLA-DR+CD38+ T



Likelihood ratio test: interaction uncorrected $p = 0.0027$ (**)







CD4 EM HLA-DR+CD38+ T

Likelihood ratio test: interaction uncorrected $p = 0.002$ (**)





CD4 EMRA HLA-DR+CD38+ T

Likelihood ratio test: interaction uncorrected $p = 0.03$ (*)




CD4 Non-naïve HLA-DR+CD38+ T


Likelihood ratio test: interaction uncorrected $p = 0.00052$ (***)



CD4 Tfh-like



Likelihood ratio test: interaction uncorrected $p = 0.0044$ (**)







Treg

Likelihood ratio test: interaction uncorrected $p = 0.0079$ (**)





Treg HLA-DR+

Likelihood ratio test: interaction uncorrected $p = 0.0011$ (**)




Treg Helios+









Likelihood ratio test: interaction uncorrected $p = 0.0067$ (**)




CD4 CCR6+

Likelihood ratio test: interaction uncorrected $p = 0.0021$ (**)











CD8 CM T

Likelihood ratio test: interaction uncorrected $p = 0.0029$ (**)





CD8 AE Tscm

Likelihood ratio test: interaction uncorrected $p = 0.078$ (-)




CD8 EM T


Likelihood ratio test: interaction uncorrected $p = 6.2e-07$ (****)



CD8 EMRA T



Likelihood ratio test: interaction uncorrected $p = 0.00041$ (***)







CD8 Total HLA-DR+CD38+ T

Likelihood ratio test: interaction uncorrected $p = 1.1e-08$ (****)





CD8 CM HLA-DR+CD38+ T

Likelihood ratio test: interaction uncorrected $p = 1.8e-06$ (****)




CD8 EM HLA-DR+CD38+ T


Likelihood ratio test: interaction uncorrected $p = 1.3e-11$ (****)



CD8 EMRA HLA-DR+CD38+ T



Likelihood ratio test: interaction uncorrected $p = 1e-07$ (****)







CD8 Non-naive HLA-DR+CD38+ T

Likelihood ratio test: interaction uncorrected $p = 1.3e-11$ (****)





CD8 CD161+

Likelihood ratio test: interaction uncorrected $p = 2.1e-05$ (****)




CD8 CXCR5+


Likelihood ratio test: interaction uncorrected $p = 0.0011$ (**)



CD8 CRTh2+



Likelihood ratio test: interaction uncorrected $p = 0.00017$ (***)







CD8 MPEC (KLRG1- CD127+)

Likelihood ratio test: interaction uncorrected p = 9e-05 (****)





CD8 DPEC (KLRG1+ CD127+)

Likelihood ratio test: interaction uncorrected p = 0.00074 (***)




CD8 SLEC (KLRG1+ CD127-)


Likelihood ratio test: interaction uncorrected p = 2.3e-05 (****)



CD8 EEC (KLRG1- CD127-)



Likelihood ratio test: interaction uncorrected p = 1.2e-05 (****)







gdT

Likelihood ratio test: interaction uncorrected $p = 2.9e-05$ (****)





Vg9Vd2(hi) gd T

Likelihood ratio test: interaction uncorrected $p = 0.0028$ (**)




Vg9Vd2(lo) gd T



Likelihood ratio test: interaction uncorrected $p = 0.58$












MAIT

Likelihood ratio test: interaction uncorrected $p = 0.00019$ (***)













Transitional B

Likelihood ratio test: interaction uncorrected $p = 0.0045$ (**)





Double neg. B

Likelihood ratio test: interaction uncorrected $p = 0.023$ (*)




Total Memory B


Likelihood ratio test: interaction uncorrected $p = 0.062$ (.)



Plasmablasts



Likelihood ratio test: interaction uncorrected $p = 0.16$







MZ-like B

Likelihood ratio test: interaction uncorrected $p = 0.42$





pDCs

Likelihood ratio test: interaction uncorrected $p = 0.033 (*)$




mDCs


Likelihood ratio test: interaction uncorrected $p = 0.00025 (***)$



mDC CD141+



Likelihood ratio test: interaction uncorrected $p = 0.091 (.)$







mDC CD1c+

Likelihood ratio test: interaction uncorrected $p = 0.00011$ (***)





Classical mon.

Likelihood ratio test: interaction uncorrected $p = 0.074$ (.)




Intermediate mon.

Likelihood ratio test: interaction uncorrected $p = 0.4$




Non-Classical mon.

Likelihood ratio test: interaction uncorrected $p = 0.33$





Days post screening or symptom onset

Days post screening or symptoms onset





Neutrophils

Likelihood ratio test: interaction uncorrected $p = 0.064$ (.)





CD66b- Neutrophils

Likelihood ratio test: interaction uncorrected $p = 0.8$




Eosinophils


Likelihood ratio test: interaction uncorrected $p = 0.00074$ (***)



Basophils



Likelihood ratio test: interaction uncorrected $p = 0.0023$ (**)





Reticulocytes

Likelihood ratio test: interaction uncorrected $p = 0.0017$ (**)



Hb

Likelihood ratio test: interaction uncorrected $p = 0.00066$ (***)






Figure S4: Whole blood transcriptomic signatures over time – extended figure 3


A



B



C



D

Module	Annotation
Positively correlated in all severity groups during active disease	
MEcyan	Histones
MEblue	TNFα/IL-6
MEpink	Complement/Coagulation/Neut degranulation
MEMidnightblue	Platelet activation
MEgrey60	Ferroptosis
MEroyalblue	Glycolysis
Positively correlated at all time points except late severe	
MEgreenyellow	Immunoglobulins
MEgreen	Interferon Stimulated Genes
Positively correlated in late mod/severe groups	
MEbrown	Heme metabolism
Positively correlated in late severe group	
MEyellow	Oxidative Phosphorylation
Negatively correlated with disease especially in early mod/severe disease	
MEdarkgrey	GPCR
MElightgreen	Ribosomal proteins
EMagenta	MYC targets
Negatively correlated with disease especially in late severe group	
METurquoise	Gene transcription
MEpurple	Splicesome
MElightyellow	BCR signalling
MElightcyan	IL-2/NK

E













Figure S5: Multivariate analysis of immune-cell populations in early disease - Extensive

fig. 4.

A




B




CD4 EM HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.0017, adj. p = 0.0076 (**)




CD4 EMRA HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.18, adj. p = 0.23




CD4 Non-naive HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.00038, adj. p = 0.0038 (**)




CD4 Tfh-like

Likelihood ratio test: interaction p = 0.018, adj. p = 0.035 (*)




Treg

Likelihood ratio test: interaction p = 0.00025, adj. p = 0.0037 (**)




Treg HLA-DR+

Likelihood ratio test: interaction p = 0.002, adj. p = 0.0076 (**)




Treg Helios+









Likelihood ratio test: interaction p = 0.0018, adj. p = 0.0076 (**)



CD4 CCR6+


Likelihood ratio test: interaction p = 0.0062, adj. p = 0.016 (*)






CD8 Total HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.012, adj. p = 0.027 (*)




CD8 CM HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.011, adj. p = 0.027 (*)




CD8 EM HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 6.7e-05, adj. p = 0.0034 (**)




CD8 EMRA HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.026, adj. p = 0.048 (*)




CD8 Non-naïve HLA-DR+CD38+ T

Likelihood ratio test: interaction p = 0.00041, adj. p = 0.0038 (**)




CD8 CD161+

Likelihood ratio test: interaction p = 0.0019, adj. p = 0.0076 (**)




CD8 CXCR5+

Likelihood ratio test: interaction p = 0.0052, adj. p = 0.014 (*)




CD8 CRTH2+


Likelihood ratio test: interaction p = 0.0026, adj. p = 0.0088 (**)




Eosinophils




CD8 MPEC (KLRG1- CD127+)




CD8 DPEC (KLRG1+ CD127+)




CD8 SLEC (KLRG1+ CD127-)




CD8 EEC (KLRG1- CD127-)




gdT



Vg9Vd2(hi) gd T




Vg9Vd2(lo) gd T




MAIT

Likelihood ratio test: interaction p = 0.053, adj. p = 0.08 (.)




CD4 MAIT

Likelihood ratio test: interaction p = 0.25, adj. p = 0.3




CD8 MAIT

Likelihood ratio test: interaction p = 0.053, adj. p = 0.08 (.)




Vb11+ abT

Likelihood ratio test: interaction p = 0.00018, adj. p = 0.0034 (**)




NKT

Likelihood ratio test: interaction p = 0.022, adj. p = 0.043 (*)




NK

Likelihood ratio test: interaction p = 0.0022, adj. p = 0.0078 (**)




NK CD16hi

Likelihood ratio test: interaction p = 0.00018, adj. p = 0.0034 (**)




NK CD56hi

Likelihood ratio test: interaction p = 0.047, adj. p = 0.074 (.)




Naive B

Likelihood ratio test: interaction p = 0.39, adj. p = 0.43




Transitional B

Likelihood ratio test: interaction p = 0.017, adj. p = 0.034 (*)




Double neg. B

Likelihood ratio test: interaction p = 0.11, adj. p = 0.15




Total Memory B

Likelihood ratio test: interaction p = 0.69, adj. p = 0.7




Plasmablasts

Likelihood ratio test: interaction p = 0.027, adj. p = 0.048 (*)




MZ-like B

Likelihood ratio test: interaction p = 0.04, adj. p = 0.067 (-)




pDCs

Likelihood ratio test: interaction p = 0.56, adj. p = 0.58




Basophils

Likelihood ratio test: interaction p = 0.084, adj. p = 0.12




mDCs

Likelihood ratio test: interaction p = 7e-04, adj. p = 0.0049 (**)




mDC CD141+

Likelihood ratio test: interaction p = 0.91, adj. p = 0.91




mDC CD1c+

Likelihood ratio test: interaction p = 0.0089, adj. p = 0.021 (*)




Classical mon.

Likelihood ratio test: interaction p = 0.074, adj. p = 0.11




Intermediate mon.

Likelihood ratio test: interaction p = 0.41, adj. p = 0.44




Non-Classical mon.

Likelihood ratio test: interaction p = 0.39, adj. p = 0.43




Neutrophils

Likelihood ratio test: interaction p = 0.36, adj. p = 0.41




CD66b- Neutrophils


Likelihood ratio test: interaction p = 0.36, adj. p = 0.41



C



D



E





Figure S6: SARS-CoV-2 specific T cell response – extended fig.5E





Figure S7: Correlation plots – extended fig.7C.

A

Correlation at 0–24 days post symptom onset (*p<0.05, **p<0.01, ***p<0.001)



B

Correlation at 0–24 days post symptom onset (*p<0.05, **p<0.01, *p<0.001)**








Figure S8: Flow cytometry gating strategy

A



B





E

